Sign In
Buy AMPH
$19.94
-0.440 (-2.16%)
At Close: Jul 31, 2026
7 Safe Small-Cap Stocks to Buy Now
10:25am, Thursday, 12'th May 2022
If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy. The post 7 Safe Small-Cap Stocks to Buy Now appeared first on InvestorPlace.
Has Amphastar Pharmaceuticals (AMPH) Outpaced Other Medical Stocks This Year?
01:40pm, Wednesday, 11'th May 2022 Zacks Investment Research
Here is how Amphastar Pharmaceuticals (AMPH) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Has Amphastar Pharmaceuticals (AMPH) Outpaced Other Medical Stocks This Year?
11:17am, Wednesday, 11'th May 2022
Here is how Amphastar Pharmaceuticals (AMPH) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Amphastar Pharmaceuticals (AMPH) Q1 2022 Earnings Call Transcript
09:00am, Tuesday, 10'th May 2022 The Motley Fool
AMPH earnings call for the period ending March 31, 2022.
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
10:05pm, Monday, 09'th May 2022 Zacks Investment Research
Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
07:33pm, Monday, 09'th May 2022
Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q1 2022 Results - Earnings Call Transcript
06:29pm, Monday, 09'th May 2022
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dan Dischner - VP, Corporate Communications Bill Peters - CFO Conference Cal
Is a Surprise Coming for Amphastar Pharmaceuticals (AMPH) This Earnings Season?
12:50pm, Wednesday, 04'th May 2022 Zacks Investment Research
Amphastar Pharmaceuticals (AMPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for Amphastar Pharmaceuticals (AMPH) This Earnings Season?
10:32am, Wednesday, 04'th May 2022
Amphastar Pharmaceuticals (AMPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022
04:05pm, Monday, 02'nd May 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 2, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, afte
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
02:54pm, Monday, 02'nd May 2022 Zacks Investment Research
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
12:02pm, Monday, 02'nd May 2022
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
04:35pm, Thursday, 28'th Apr 2022
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Amphastar (AMPH) Keep the Earnings Surprise Streak Alive?
04:10pm, Friday, 22'nd Apr 2022 Zacks Investment Research
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
